Invention Grant
- Patent Title: Method to identify key markers of human pluripotent cell-derived somatic cells that predict molecular similarity to in vivo target cells
-
Application No.: US16068323Application Date: 2017-01-06
-
Publication No.: US11359242B2Publication Date: 2022-06-14
- Inventor: Ritchie Ho , Clive Svendsen
- Applicant: Cedars-Sinai Medical Center
- Applicant Address: US CA Los Angeles
- Assignee: Cedars-Sinai Medical Center
- Current Assignee: Cedars-Sinai Medical Center
- Current Assignee Address: US CA Los Angeles
- Agency: Nixon Peabody LLP
- International Application: PCT/US2017/012492 WO 20170106
- International Announcement: WO2017/120443 WO 20170713
- Main IPC: C12Q1/6883
- IPC: C12Q1/6883 ; A61K35/30 ; C12Q1/6881 ; G01N33/68

Abstract:
Modeling Amyotrophic Lateral Sclerosis (ALS) with human induced pluripotent stem cells (iPSCs) aims to reenact embryogenesis, maturation, and aging of spinal motor neurons (spMNs) in vitro. As the maturity of spMNs grown in vitro compared to spMNs in vivo remains largely unaddressed, it is unclear to what extent this in vitro system captures critical aspects of spMN development and molecular signatures associated with ALS. Here, the Inventors compared transcriptomes among iPSC-derived spMNs, fetal, and adult spinal tissues. The Inventors resolved gene networks and pathways associated with spMN maturation and aging. These networks enriched for familial ALS genetic variants and were affected in sporadic ALS. Altogether, the Inventors' findings suggest that developing strategies to further mature and age iPSC-derived spMNs will provide more effective iPSC models of ALS.
Public/Granted literature
Information query